Clinical studies demonstrated that transfer of ex vivo IL-2 expanded autologous NK cells alone or in combination with subcutaneous administration of IL-2 was safe and feasible in the treatment of solid tumors as well as hematological diseases [73]. The gene discussed is IL2; the disease is hematologic disorder.